Sickle cell disease (SCD), which affects millions of people worldwide, has traditionally been treated with a cytotoxic drug that has a range of negative side effects and variable patient response. Bay Area biopharmaceutical company Global Blood Therapeutics (GBT) is on a mission to develop a better treatment and is using the ALS to help. Read more »
Bacterial microcompartments (BMCs) are hollow protein shells that encapsulate enzymes involved in bacterial metabolism. Crystallography studies have provided atomic-resolution views of a fully assembled BMC, revealing basic principles of shell construction for fighting pathogens or bioengineering applications. Read more »
A noncanonical amino-acid (NCAA) complex has been found to drive the self-assembly of a computationally designed protein. Bpy-ala, which is “noncanonical” because it’s not among the 20 amino acids that occur naturally, has useful properties that could be used to generate novel photoactive proteins. Read more »
In a first-of-its-kind experiment, ALS researchers demonstrated a new, direct way to study the inner workings of a phenomenon in chemistry known as an “electrochemical double layer” that forms where liquids meet solids—where battery fluid meets an electrode, for example. Read more »
A beamstop device recently developed at the ALS has successfully combined two essential crystallographic functions–capturing the damaging portion of the beam while simultaneously monitoring its intensity–into a single miniaturized package. The technology has been licensed and launched commercially and is also a finalist for an R&D 100 Award. Read more »
Type 2 diabetes mellitus (T2DM), characterized by abnormally high blood glucose levels, affects hundreds of millions of people worldwide. In the pursuit to better treat this disease, the human receptor protein GPR40 has been identified by pharmaceutical company Takeda as a potential new drug target.
Genentech has developed a unique one-armed antibody, onartuzumab, which is now in late-stage clinical trials in multiple cancer types. The company used crystal structures obtained at ALS Beamline 5.0.2 to demonstrate the mechanism of action of this unique potentially therapeutic antibody. Read more »